Sulfasalazine related nephrolithiasis in patients with rheumatoid arthritis and ankylosing spondylitis

Authors : Gülşah ŞAŞAK KUZGUN, Sadiye MURAT, Serçin ÖZKÖK, Esen KASAPOGLU

Pages : 101-105

Doi:10.46310/tjim.1058021

View : 18 | Download : 16

Publication Date : 2022-07-29

Article Type : Research Paper

Abstract :Background Sulfasalazine insert ignore into journalissuearticles values(SSZ); is an anti-inflammatory and immunomodulatory drug used to treat many inflammatory diseases. Bacteria in the gut metabolize SSZ to active 5-aminosalicylic acid and inactive sulfapyridine. Sulfapyridine can crystallize in the kidney. We aimed to investigate the frequency of nephrolithiasis in patients who were diagnosed with rheumatoid arthritis insert ignore into journalissuearticles values(RA);, ankylosing spondylitis insert ignore into journalissuearticles values(AS); and who received SSZ treatment retrospectively. Material and Methods We retrospectively analyzed the files of AS and RA patients in the rheumatology outpatient clinic between 2009 and 2018. We identified patients who underwent kidney ultrasonography at least six months after initiation of SSZ. One hundred six patients and 50 healthy adults were included in the study. Results Only eight patients insert ignore into journalissuearticles values(6 AS, 2 RA); had nephrolithiasis on ultrasonography, but none in the control group insert ignore into journalissuearticles values(p=0.046);. In logistic regression analysis, no correlation was found between gender, age, vitamin D, parathyroid hormone, and urinary calcium excretion with SSZ use insert ignore into journalissuearticles values(p>0.05);. Conclusion Although, it is noteworthy that these patients are prone to stone formation for various reasons. Therefore, paying attention to the patient’s hydration while using these drugs may prevent such side effects.
Keywords : nephrolithiasis, Sulfasalazine, rheumatoid arthritis, ankylosing spondylitis